Novartis AG stock (CH0012005267): Q1 2026 earnings miss EPS consensus as revenue dips slightly year-on-year

Novartis AG reported first-quarter 2026 earnings that missed EPS expectations while revenue slightly exceeded estimates but fell 0.9% year-on-year, highlighting margin pressure in a competitive pharmaceutical landscape.

Novartis AG reported first-quarter 2026 earnings that missed EPS expectations while revenue slightly exceeded estimates but fell 0.9% year-on-year, highlighting margin pressure in a competitive pharmaceutical landscape. The company posted quarterly EPS of $1.99, below the $2.11 consensus, while revenue came in at $13.52 billion, just above the $13.44 billion estimate, according to a recent earnings recap from MarketBeat as of May 5, 2026. Novartis AG’s first-quarter 2026 results show a company navigating a complex environment: revenue slightly above estimates but down year-on-year, and EPS below consensus, reflecting margin pressure and competitive dynamics.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis AG
• Sector/industry: Pharmaceuticals
• Headquarters/country: Basel, Switzerland
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Oncology, immunology, neuroscience, cardiovascular, and other therapeutic areas
• Home exchange/listing venue: NYSE (ticker: NVS)
• Trading currency: USD

Novartis AG: core business model

Novartis AG operates a resilient big pharma business model focused on discovering and manufacturing blockbuster medicines across oncology, immunology, and neuroscience. The company generates substantial revenue from its diversified portfolio of prescription drugs and therapies, with a strong emphasis on innovation and research and development. Novartis AG’s strategic investments in radioligand therapy and other innovative platforms position it for long-term growth, particularly in the United States, but also entail ongoing costs and execution risk.

Novartis AG’s business model is characterized by high margins and significant cash flow generation, supported by a robust pipeline of new products and indications. The company’s focus on blockbuster medicines and its global footprint enable it to maintain a leading position in key therapeutic areas. However, the competitive pharmaceutical landscape and pricing pressures pose challenges to sustaining profitability and growth.

Main revenue and product drivers for Novartis AG

Novartis AG’s main revenue drivers include its oncology, immunology, and neuroscience franchises, which contribute a significant portion of the company’s total sales. The company’s oncology portfolio features several blockbuster drugs that address unmet medical needs and command premium pricing. Immunology and neuroscience products also play a crucial role in driving revenue growth, supported by strong demand and favorable reimbursement environments.

Novartis AG’s product pipeline includes a range of innovative therapies and indications that are expected to contribute to future revenue growth. The company’s investments in radioligand therapy and other cutting-edge technologies aim to expand its addressable market and enhance its competitive position. However, the success of these initiatives depends on successful clinical development, regulatory approval, and commercial execution.

Conclusion

Novartis AG’s first-quarter 2026 results show a company navigating a complex environment: revenue slightly above estimates but down year-on-year, and EPS below consensus, reflecting margin pressure and competitive dynamics. The company’s strategic investments in radioligand therapy and other innovative platforms position it for long-term growth, particularly in the United States, but also entail ongoing costs and execution risk. For US investors, Novartis offers exposure to a diversified pharma portfolio with a strong pipeline, yet the stock’s performance will hinge on successful innovation, effective cost control, and the ability to sustain profitability amid pricing and regulatory challenges.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.